ArticlePloS one2010
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00261456 (The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer), which is not on this map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer: Targeted Screening in Men at Higher Genetic Risk and Controls
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.Human molecular genetics · 2020Pooled it
- Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.Nature communications · 2018Pooled it
- Pooled it
- Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health technology assessment (Winchester, England) · 2020Trial
- Genomic and transcriptomic correlates of deep prostate-specific antigen response in patients with metastatic androgen pathway modulation-sensitive prostate cancer.The oncologist · 2026Article
- CAP superfamily proteins in human: a new target for cancer therapy.Medical oncology (Northwood, London, England) · 2024Review
- Single nucleotide polymorphism within chromosome 8q24 is associated with prostate cancer development in Saudi Arabia.Asian journal of urology · 2024Article
- Identification and validation ofAmerican journal of cancer research · 2023Article
- Morbid Obesity in Women Is Associated with an Altered Intestinal Expression of Genes Related to Cancer Risk and Immune, Defensive, and Antimicrobial Response.Biomedicines · 2022Article
- Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.BJU international · 2021Article
- Article
- DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs.PLoS genetics · 2020Article
- Prostate Cancer Germline Variations and Implications for Screening and Treatment.Cold Spring Harbor perspectives in medicine · 2018Review
- Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity.Nature communications · 2018Article
- Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.Oncotarget · 2018Article
- Article
- Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90.Cancers · 2016Article
- Overexpression and purification of folded domain of prostate cancer related proteins MSMB and PSA.Molecular biology reports · 2016Article
- Biomarkers for prostate cancer: present challenges and future opportunities.Future science OA · 2016Review
- Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.Future science OA · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 6 countries.
Funding
Abstract
backgroundMicroseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk. METHODOLOGY/PRINCIPAL
findingsMSMB expression in benign and malignant prostate tissue was examined using immunohistochemistry and compared with the rs10993994 genotype. Urinary MSMB concentrations were determined by ELISA and correlated with urinary PSA, the presence or absence of cancer, rs10993994 genotype and age of onset. MSMB levels in prostate tissue and urine were greatly reduced with tumourigenesis. Urinary MSMB was better than urinary PSA at differentiating men with prostate cancer at all Gleason grades. The high risk allele was associated with heterogeneity of MSMB staining and loss of MSMB in both tissue and urine in benign prostate.
conclusionsThese data show that some high risk alleles discovered using genome-wide association studies produce phenotypic effects with potential clinical utility. We provide the first link between a low penetrance polymorphism for prostate cancer and a potential test in human tissue and bodily fluids. There is potential to develop tissue and urinary MSMB for a biomarker of prostate cancer risk, diagnosis and disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.